CXCR4 pepducins in combination with rituximab increase survival in a mouse model of disseminated lymphoma. (A) NOD/SCID/γ mice were injected IV with 2 × 106 Raji cells, then treated daily with subcutaneous injections of vehicle, PZ-210, PZ-218, plerixafor (AMD3100), or biweekly with rituximab, as described in “In vivo systemic lymphoma mouse model.” Survival is shown by Kaplan-Meier analysis (n = 10 mice per treatment group). (B) Mice were injected with Raji cells and then treated with a combination of rituximab and PZ-218, PZ-210, or plerixafor (AMD3100). Survival was monitored and plotted using Kaplan-Meier analysis (n = 10 mice per group, except for AMD3100-treated cohort, where n = 9). Statistical significance between groups was determined using the log-rank test.
